Lv7
3610 积分 2021-09-09 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
5天前
已完结
Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy
1个月前
已完结
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
1个月前
已完结
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
1个月前
已完结
Pneumopathies interstitielles diffuses induites par les anticorps conjugués
1个月前
已关闭
High prevalence of pneumocystis pneumonia in interstitial lung disease: a retrospective study
1个月前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
1个月前
已关闭
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
1个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
1个月前
已完结
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
4个月前
已完结
皖公网安备34019202002308
